Mount Sinai (Icahn) Selects MediPharma Labs to Support 500 Patient Clinical Trial

May 24, 2019 | CBD, CNS, Opioid Reduction

CBD Clinical Trial

Icahn School of Medicine, Mount Sinai, has selected MediPharma Labs to support a large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.

The trial is led by a renowned investigator, Dr. Yasmin L. Hurd, PhD, the Ward-Coleman Chair of Translational Neuroscience at the Icahn School of Medicine and Director of the Addiction Institute at Mount Sinai and Center for Addictive Disorders for the Mount Sinai Behavioral Health System.

Additionally, MediPharm was selected to participate in an Icahn School of Medicine clinical trial involving Courtney Betty of Timeless Care Inc. (Timeless Herbal), a fully integrated licensed producer of medicinal cannabis in Jamaica.

According to the MediPharm originated press release, MediPharm Labs will be the exclusive manufacturer of a proprietary hemp-derived CBD oral gelcap medication utilizing the Formula provided by Timeless Herbal for all phases of the clinical trials related to this study that will allow researchers to test an investigational product containing CBD active ingredient.

MediPharm Labs and Timeless Herbal will jointly own any generated intellectual property.

About the Trial

Phase II and Phase III trials will be conducted in two stages and will be a randomized, double-blinded, placebo-controlled study in which at least 500 participants will be studied in different stages. The study will also include a multisite evaluation that will gather evidence of the safety and efficacy of CBD in opioid reduction through anti-anxiety intervention in patients around the world.

About MediPharm Labs

MediPharm Labs is a leading provider of high-quality, industrial-scale cannabinoid-based derivatives and extraction services.  See their investor presentation.

Lead Research/Investigator

Dr. Yasmin L. Hurd, PhD


Pin It on Pinterest